Citius Pharmaceuticals, Inc.
CTXR
$0.85
$0.000.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.47% | -8.94% | 1.76% | 17.77% | 12.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.65% | -17.36% | 2.65% | 7.48% | 9.14% |
| Operating Income | 23.65% | 17.36% | -2.65% | -7.48% | -9.14% |
| Income Before Tax | 22.44% | 14.28% | -33.89% | -10.23% | -11.56% |
| Income Tax Expenses | 83.47% | 83.47% | 83.47% | 83.47% | 0.00% |
| Earnings from Continuing Operations | 21.07% | 12.95% | -34.73% | -11.37% | -11.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 173.31% | -- | -- | -- | -- |
| Net Income | 26.24% | 16.87% | -27.77% | -5.82% | -8.51% |
| EBIT | 23.65% | 17.36% | -2.65% | -7.48% | -9.14% |
| EBITDA | 23.65% | 17.36% | -2.65% | -7.48% | -9.15% |
| EPS Basic | 70.93% | 49.02% | 5.27% | 10.20% | 8.79% |
| Normalized Basic EPS | 70.99% | 49.86% | 29.24% | 14.12% | 6.07% |
| EPS Diluted | 70.93% | 49.02% | 5.27% | 10.20% | 11.09% |
| Normalized Diluted EPS | 70.99% | 49.86% | 29.24% | 14.12% | 6.07% |
| Average Basic Shares Outstanding | 137.75% | 58.27% | 34.86% | 17.84% | 13.79% |
| Average Diluted Shares Outstanding | 137.75% | 58.27% | 34.86% | 17.84% | 13.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |